Page last updated: 2024-12-11
cgc 11047
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CGC 11047: may prove useful in promoting regression of choroidal neovascularization [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9822383 |
CHEMBL ID | 4296681 |
MeSH ID | M0504975 |
Synonyms (17)
Synonym |
---|
206991-64-2 |
cgc-11047 |
sl 47 |
sl 11047 |
hu43305r7o , |
cdc 11047 |
cgc 11047 |
unii-hu43305r7o |
2-butene-1,4-diamine, n,n'-bis(3-(ethylamino)propyl)-, tetrahydrochloride, (z)- |
CHEMBL4296681 |
cgc-11047 hcl |
206991-64-2 (hcl) |
(z)-n1,n1'-(but-2-ene-1,4-diyl)bis(n3-ethylpropane-1,3-diamine) tetrahydrochloride |
(z)-n,n'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine;tetrahydrochloride |
CS-0006318 |
pg-11047 (tetrahydrochloride) |
HY-16394 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (30)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID58070 | The concentration levels of analogue evaluated in DU145 cells treated with the compound concentration of 5 uM on third day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID285446 | Prevention of Cryptosporidium parvum infection in TCR alpha deficient-mouse pretreated with 50 mg/kg/day, po for 2 days prior to oocyst infection and continued for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Activities of DL-alpha-difluoromethylarginine and polyamine analogues against Cryptosporidium parvum infection in a T-cell receptor alpha-deficient mouse model. |
AID103583 | Growth inhibitory activity was measured for human MCF-7 tumor cell line. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID58218 | The concentration levels of spermine (SP) evaluated in DU145 cells treated with the compound concentration of 0.02 uM on fifth day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID421197 | Antitumor activity against human MCF7 cells | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Recent advances in the development of polyamine analogues as antitumor agents. |
AID58079 | The concentration levels of putrescine (PU) evaluated in DU145 cells treated with the compound concentration of 5 uM on third day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID214255 | Growth inhibitory activity was measured for human U251MG NCI tumor cell line. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID58080 | The concentration levels of spermidine (SD) evaluated in DU145 cells treated with the compound concentration of 0.02 uM on fifth day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID58071 | The concentration levels of putrescine (PU) evaluated in DU145 cells treated with the compound concentration of 0.02 uM on fifth day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID58064 | The concentration levels of analogue evaluated in DU145 cells treated with the compound concentration of 0.02 uM on third day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID58069 | The concentration levels of analogue evaluated in DU145 cells treated with the compound concentration of 5 uM on fifth day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID8694 | Growth inhibitory activity was measured for human A549 tumor cell line. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID421191 | Antitumor activity against human DU145 cells | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Recent advances in the development of polyamine analogues as antitumor agents. |
AID58089 | The concentration levels of spermidine (SD), evaluated in DU145 cells treated with the compound concentration of 5 uM on third day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID58084 | The concentration levels of spermidine (SD) evaluated in DU145 cells treated with the compound concentration of 5 uM on fifth day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID58073 | The concentration levels of putrescine (PU) evaluated in DU145 cells treated with the compound concentration of 0.02 uM on third day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID421194 | Antitumor activity against human A549 cells | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Recent advances in the development of polyamine analogues as antitumor agents. |
AID421193 | Antitumor activity against human PC3 cells | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Recent advances in the development of polyamine analogues as antitumor agents. |
AID58222 | The concentration levels of spermine (SP) evaluated in DU145 cells treated with the compound concentration of 5 uM on fifth day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID55811 | Growth inhibitory activity was measured for human DU145 tumor cell line. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID285449 | Anticryptosporidial activity against Cryptosporidium parvum infected TCR alpha deficient-mouse assessed as prevention of oocyst shedding at 134 mg/kg/day after 7 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Activities of DL-alpha-difluoromethylarginine and polyamine analogues against Cryptosporidium parvum infection in a T-cell receptor alpha-deficient mouse model. |
AID58224 | The concentration levels of spermine (SP), evaluated in DU145 cells treated with the compound concentration of 0.02 uM on third day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID58062 | The concentration levels of analogue evaluated in DU145 cells treated with the compound concentration of 0.02 uM on fifth day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID83766 | Growth inhibitory activity was measured for human HT-29 tumor cell line. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID58086 | The concentration levels of spermidine (SD), evaluated in DU145 cells treated with the compound concentration of 0.02 uM on third day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID421196 | Antitumor activity against human U251MG cells | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Recent advances in the development of polyamine analogues as antitumor agents. |
AID58078 | The concentration levels of putrescine (PU) evaluated in DU145 cells treated with the compound concentration of 5 uM on fifth day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID58227 | The concentration levels of spermine (SP), evaluated in DU145 cells treated with the compound concentration of 5 uM on third day of treatment. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
AID421195 | Antitumor activity against human HT-29 cells | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Recent advances in the development of polyamine analogues as antitumor agents. |
AID156179 | Growth inhibitory activity was measured for human PC-3 tumor cell line. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 6 (85.71) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 18.15
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.15) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (14.29%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (85.71%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |